Overview

Antimicrobial Catheter Lock Solution for the Treatment of Central Line Associated Bloodstream Infection (CLABSI)

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
0
Participant gender:
All
Summary
A CVC is a sterile flexible tube that allows a drug to flow from a bottle or bag directly into a patient's bloodstream. CVCs may cause infections when bacteria gets into the catheter and enters the bloodstream. They also have a risk of becoming clogged. When this occurs, the CVC usually needs to be replaced. The goal of this clinical research study is to learn if an antimicrobial catheter lock solution can make it possible for the CVC to stay in place while treating an infection with antibiotics. The safety of the solution will also be tested. Your outcome will be compared to the outcome of patients who had the same type of infection but had their CVC removed. The antimicrobial catheter lock solution is made up of 3 chemicals: Minocycline and ethanol are designed to disinfect the CVC. Disodium ethylenediaminetetraacetate is designed to prevent the CVC from clogging.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Triax
Treatments:
Anti-Bacterial Agents
Anti-Infective Agents
Pharmaceutical Solutions
Criteria
Inclusion Criteria:

1. Patients aged 18 years or older

2. Patients with indwelling CVC that have been in place for at least 14 days with
documented CLABSI as defined by CDC [62]. In neutropenic patients (defined as an
absolute neutrophil count (ANC) < 500 cells/mm3) with CLABSI, to confirm that CVC is
the source of the bacteremia, we will use the definitions of catheter-related
bloodstream infection (CRBSI) based on the mgmt guidelines of intravascular catheter
related infections published by IDSA [10]. This includes the evidence that points to
the CVC as the culprit: a) Paired quantitative blood cultures (QBC), whereby QBC are
drawn through the CVC and peripheral vein and the blood cultures from the CVC reveal
3-fold greater number of colonies than the peripherally drawn QBC. b) Differential
time to positivity, where blood cultures simultaneously drawn from the CVC and
peripheral vein are positive for the same organism, and the catheter-drawn blood
culture turns positive at least 2 hours earlier than the peripherally drawn blood
culture.

3. Female patients must be non-lactating and at no risk for pregnancy for one of the
following reasons: a) Postmenopausal for at least one year b) Post-hysterectomy and/or
post-bilateral ovariectomy and/or other surgical sterilization c) If of childbearing
potential, having a negative urine or serum human chorionic gonadotropin (hCG)
pregnancy test within 5 days prior to study enrollment and be using a highly effective
method of birth control throughout the course of the study. Reliable sexual abstinence
throughout the course of the study is acceptable as a highly effective method of birth
control for the purposes of this study.

4. Patients with short term non-tunneled catheters will be enrolled only if CVC cannot be
removed or exchanged (patient refuses to have CVC removed, CVC needed and no other
vascular access available, patient is thrombocytopenic (platelet count below 20,000)
that will prohibit inserting a new CVC at a different site).

Exclusion Criteria:

1. Patients allergic to tetracycline antibiotics or calcium EDTA

2. Patients on disulfiram or disulfiram like drugs

3. Patients with severe sepsis, septic shock, hypotension or who are considered otherwise
unstable

4. Presence of prosthetic valve

5. Presence of signs of metastatic deep-seated infection such as osteomyelitis or septic
pulmonary infarcts or endocarditis (as evidenced by vegetations on an echocardiogram),
or septic thrombosis

6. Patients with tunnel or catheter exit site infection or infusion port pocket abscess
as manifested by purulence at the exit site or inflammation with erythema or
induration of >1 cm in diameter.

7. Patients with Candida line infection

8. Patients who have been previously entered on the study